256 related articles for article (PubMed ID: 32004652)
1. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Sun J; Wan Z; Chen Y; Xu J; Luo Z; Parise RA; Diao D; Ren P; Beumer JH; Lu B; Li S
Acta Biomater; 2020 Apr; 106():289-300. PubMed ID: 32004652
[TBL] [Abstract][Full Text] [Related]
2. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy.
Sun J; Chen Y; Xu J; Song X; Wan Z; Du Y; Ma W; Li X; Zhang L; Li S
Theranostics; 2020; 10(3):1136-1150. PubMed ID: 31938056
[TBL] [Abstract][Full Text] [Related]
3. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
4. An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy.
Chen Y; Xia R; Huang Y; Zhao W; Li J; Zhang X; Wang P; Venkataramanan R; Fan J; Xie W; Ma X; Lu B; Li S
Nat Commun; 2016 Nov; 7():13443. PubMed ID: 27819653
[TBL] [Abstract][Full Text] [Related]
5. Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents.
Chen Y; Sun J; Huang Y; Lu B; Li S
Mol Pharm; 2018 Nov; 15(11):5162-5173. PubMed ID: 30222360
[TBL] [Abstract][Full Text] [Related]
6. Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier.
Sun JJ; Chen YC; Huang YX; Zhao WC; Liu YH; Venkataramanan R; Lu BF; Li S
Acta Pharmacol Sin; 2017 Jun; 38(6):823-834. PubMed ID: 28504251
[TBL] [Abstract][Full Text] [Related]
7. NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel.
Xu J; Ren X; Guo T; Sun X; Chen X; Patterson LH; Li H; Zhang J
Eur J Pharm Sci; 2019 Oct; 138():105034. PubMed ID: 31382032
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
9. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
Wan Z; Sun J; Xu J; Moharil P; Chen J; Xu J; Zhu J; Li J; Huang Y; Xu P; Ma X; Xie W; Lu B; Li S
Acta Biomater; 2019 May; 90():300-313. PubMed ID: 30930305
[TBL] [Abstract][Full Text] [Related]
10. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles.
Wu ST; Fowler AJ; Garmon CB; Fessler AB; Ogle JD; Grover KR; Allen BC; Williams CD; Zhou R; Yazdanifar M; Ogle CA; Mukherjee P
BMC Cancer; 2018 Apr; 18(1):457. PubMed ID: 29685122
[TBL] [Abstract][Full Text] [Related]
11. A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel.
Sun J; Chen Y; Li K; Huang Y; Fu X; Zhang X; Zhao W; Wei Y; Xu L; Zhang P; Venkataramanan R; Li S
Acta Biomater; 2016 Oct; 43():282-291. PubMed ID: 27422196
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
[TBL] [Abstract][Full Text] [Related]
13. Tumor size-dependent abscopal effect of polydopamine-coated all-in-one nanoparticles for immunochemo-photothermal therapy of early- and late-stage metastatic cancer.
Sun J; Wan Z; Xu J; Luo Z; Ren P; Zhang B; Diao D; Huang Y; Li S
Biomaterials; 2021 Feb; 269():120629. PubMed ID: 33387938
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy.
Dong S; Guo Y; Duan Y; Li Z; Wang C; Niu L; Wang N; Ma M; Shi Y; Zhang M
Anticancer Drugs; 2018 Aug; 29(7):637-645. PubMed ID: 29846247
[TBL] [Abstract][Full Text] [Related]
15. Lymphoma Immunochemotherapy: Targeted Delivery of Doxorubicin via a Dual Functional Nanocarrier.
Zhai Q; Chen Y; Xu J; Huang Y; Sun J; Liu Y; Zhang X; Li S; Tang S
Mol Pharm; 2017 Nov; 14(11):3888-3895. PubMed ID: 28850241
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
17. Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Han H; Hou Y; Chen X; Zhang P; Kang M; Jin Q; Ji J; Gao M
J Am Chem Soc; 2020 Mar; 142(10):4944-4954. PubMed ID: 32069041
[TBL] [Abstract][Full Text] [Related]
18. A multi-functional polymeric carrier for simultaneous positron emission tomography imaging and combination therapy.
Sun J; Sun L; Li J; Xu J; Wan Z; Ouyang Z; Liang L; Li S; Zeng D
Acta Biomater; 2018 Jul; 75():312-322. PubMed ID: 29885530
[TBL] [Abstract][Full Text] [Related]
19. Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy.
Qiao H; Chen X; Chen E; Zhang J; Huang D; Yang D; Ding Y; Qian H; Feijen J; Chen W
Biomater Sci; 2019 Jun; 7(7):2749-2758. PubMed ID: 30997445
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer.
Luo Z; Xu J; Sun J; Huang H; Zhang Z; Ma W; Wan Z; Liu Y; Pardeshi A; Li S
Acta Biomater; 2020 Mar; 105():239-252. PubMed ID: 31958597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
